Skip to main content

Table 2 Risk of colorectal cancer, overall and according to clinicopathological factors, in relation to HRT and ERT use

From: Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability

Tumour subgroups HRT use Number of cases HR crude p HR adjusted p
CRC No 236 1.00   1.00  
ERT 24 0.89(0.59-1.35) 0.583 0.94(0.62-1.44) 0.788
CHRT 41 0.74(0.53-1.03) 0.076 0.94(0.67-1.31) 0.701
T stage 1 & 2 No 54 1.00   1.00  
ERT 3 0.53(0.17-1.70) 0.284 0.56(0.17-1.80) 0.560
CHRT 3 0.24(0.09-0.77) 0.016 0.30(0.09-0.96) 0.043
T stage 3 & 4 No 156 1.00   1.00  
ERT 17 0.93(0.56-1.52) 0.761 1.01(0.61-1.67) 0.966
CHRT 32 0.87(0.59-1.27) 0.471 1.14(0.77-1.68) 0.511
N0 No 119 1.00   1.00  
ERT 14 1.03(0.59-1.79) 0.912 1.15(0.66-2.01) 0.615
CHRT 22 0.79(0.50-1.24) 0.302 1.05(0.66-1.67) 0.838
N1 & N2 No 79 1.00   1.00  
ERT 7 0.75(0.35-1.63) 0.471 0.78(0.36-1.68) 0.522
CHRT 15 0.81(0.47-1.40) 0.449 0.95(0.54-1.67) 0.860
M0 No 181 1.00   1.00  
ERT 20 0.96(0.61-1.52) 0.863 1.04(0.66-1.66) 0.861
CHRT 34 0.80(0.55-1.15) 0.232 1.03(0.71-1.49) 0.893
M1 No 45 1.00   1.00  
ERT 4 0.78(028–2.16) 0.632 0.77(0.28-2.16) 0.625
CHRT 7 0.66(0.30-1.47) 0.311 0.80(0.36-1.80) 0.589
  1. Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.